SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-053194
Filing Date
2024-05-06
Accepted
2024-05-06 07:04:21
Documents
13
Period of Report
2024-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K omga-20240506.htm   iXBRL 8-K 42609
2 EX-99.1 omga-ex99_1.htm EX-99.1 109097
3 GRAPHIC img220583725_0.jpg GRAPHIC 16872
  Complete submission text file 0000950170-24-053194.txt   304055

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT omga-20240506.xsd EX-101.SCH 27045
16 EXTRACTED XBRL INSTANCE DOCUMENT omga-20240506_htm.xml XML 4885
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 24915513
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)